|
1
|
International Agency for Research on
Cancer (IARC), . World Cancer Report 2014. Stewart B and Wild CP:
IARC; Lyon: 2014, http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014
|
|
2
|
Brody H: Colorectal cancer. Nature.
521:S12015. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mármol I, Sánchez-de-Diego C, Pradilla
Dieste A, Cerrada E and Rodriguez Yoldi MJ: Colorectal carcinoma: A
general overview and future perspectives in colorectal cancer. Int
J Mol Sci. 18(pii): E1972017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Komaki Y, Komaki F, Micic D, Ido A and
Sakuraba A: Risk of colorectal cancer in chronic liver diseases; a
systematic review and meta-analysis. Gastrointest Endosc.
86:S93–S104.e5. 2017. View Article : Google Scholar
|
|
5
|
El-Shami K, Oeffinger KC, Erb NL, Willis
A, Bretsch JK, Pratt-Chapman ML, Cannady RS, Wong SL, Rose J,
Barbour AL, et al: American cancer society colorectal cancer
survivorship care guidelines. CA Cancer J Clin. 65:428–455. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Giardiello FM, Allen JI, Axilbund JE,
Boland CR, Burke CA, Burt RW, Church JM, Dominitz JA, Johnson DA,
Kaltenbach T, et al: Guidelines on genetic evaluation and
management of Lynch syndrome: A consensus statement by the US
multi-society task force on colorectal cancer. Gastroenterol.
147:502–526. 2014. View Article : Google Scholar
|
|
7
|
Corley DA, Levin TR and Doubeni CA:
Adenoma detection rate and risk of colorectal cancer and death. N
Engl J Med. 370:25412014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Loberg M, Kalager M, Holme Ø, Hoff G,
Adami HO and Bretthauer M: Long-term colorectal-cancer mortality
after adenoma removal. N Engl J Med. 371:799–807. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Levine AJ, Momand J and Finlay CA: The p53
tumour suppressor gene. Nature. 351:453–456. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu M, Mao C, Chen Q, Cu XW and Zhang WS:
Serum p53 protein and anti-p53 antibodies are associated with
increased cancer risk: A case-control study of 569 patients and 879
healthy controls. Mol Biol Rep. 37:339–343. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang J, Xv Z, Wu X and Li K: Potential
diagnostic value of serum p53 antibody for detecting esophageal
cancer: A meta-analysis. PLoS One. 7:e528962012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Stroup DF, Berlin JA, Morton SC, Olkin I,
Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA and Thacker
SB: Meta-analysis of observational studies in epidemiology: A
proposal for reporting. Meta-analysis of observational studies in
epidemiology (MOOSE) group. JAMA. 283:2008–2012. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moher D, Liberati A, Tetzlaff J and Altman
DG; PRISMA Group, : Preferred reporting items for systematic
reviews and metaanalyses: The PRISMA statement. Int J Surg.
8:336–341. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Smidt N, Deeks J and Moore T: Guide to the
contents of a Cochrane review and protocol. Cochrane handbook for
systematic reviews of diagnostic test accuracy. 2011.
|
|
15
|
Japanese Society for Cancer of the Colon
and Rectum Japanese classification of colorectal carcinoma. The.
8th. Kanehara & CO., LTD; Tokyo: 2013
|
|
16
|
Devillé WL, Buntinx F, Bouter LM, Montori
VM, de Vet HC, van der Windt DA and Bezemer PD: Conducting
systematic reviews of diagnostic studies: Didactic guidelines. BMC
Med Res Methodol. 2:92002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
DerSimonian R and Laird N: Meta-analysis
in clinical trials. Control Clin Trials. 7:177–188. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gu P, Huang G, Chen Y, Zhu C, Yuan J and
Sheng S: Diagnostic utility of pleural fluid carcinoembryonic
antigen and CYFRA 21-1 in patients with pleural effusion: A
systematic review and meta-analysis. J Clin Lab Anal. 21:398–405.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang J, Zhu Z, Liu Y, Jin X, Xu Z, Yu Q
and Li K: Diagnostic value of multiple tumor markers for patients
with esophageal carcinoma. PLoS One. 10:e01169512015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dinnes J, Deeks J, Kirby J and Roderick P:
A methodological review of how heterogeneity has been examined in
systematic reviews of diagnostic test accuracy. Health Technol
Assess. 9:1–133, iii. 2005. View
Article : Google Scholar
|
|
21
|
Deeks JJ, Macaskill P and Irwig L: The
performance of tests of publication bias and other sample size
effects in systematic reviews of diagnostic test accuracy was
assessed. J Clin Epidemiol. 58:882–893. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shimada H, Ochiai T and Nomura F:
Titration of serum p53 antibodies in 1,085 patients with various
types of malignant tumors: A multiinstitutional analysis by the
Japan p53 Antibody Research Group. Cancer. 97:682–689. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yoshizawa S, Matsuoka K, Inoue N, Takaishi
H, Ogata H, Iwao Y, Mukai M, Fujita T, Kawakami Y and Hibi T:
Clinical significance of serum p53 antibodies in patients with
ulcerative colitis and its carcinogenesis. Inflamm Bowel Dis.
13:865–873. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tagi T, Matsui T, Kikuchi S, Hoshi S,
Ochiai T, Kokuba Y, Kinoshita-Ida Y, Kisumi-Hayashi F, Morimoto K,
Imai T, et al: Dermokine as a novel biomarker for early-stage
colorectal cancer. J Gastroenterol. 45:1201–1211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shiota G, Ishida M, Noguchi N, Oyama K,
Takano Y, Okubo M, Katayama S, Tomie Y, Harada K, Hori K, et al:
Circulating p53 antibody in patients with colorectal cancer:
Relation to clinicopathologic features and survival. Dig Dis Sci.
45:122–128. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kojima T, Yoshikawa K, Matsui T, Kodera Y
and Kojima H: Titration of serum CEA, p53 antibodies and CEA-IgM
complexes in patients with colorectal cancer. Mol Med Rep.
2:477–480. 2009.PubMed/NCBI
|
|
27
|
Takeda A, Shimada H, Nakajima K, Yoshimura
S, Suzuki T, Asano T, Ochiai T and Isono K: Serum p53 antibody as a
useful marker for monitoring of treatment of superficial colorectal
adenocarcinoma after endoscopic resection. Int J Clin Oncol.
6:45–49. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lechpammer M, Lukač J, Lechpammer S,
Kovacević D, Loda M and Kusić Z: Humoral immune response to p53
correlates with clinical course in colorectal cancer patients
during adjuvant chemotherapy. Int J Colorectal Dis. 19:114–120.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Broll R, Duchrow M, Oevermann E, Wellm C,
Schwandner O, Schimmelpenning H, Roblick UJ, Bruch HP and Windhövel
U: p53 autoantibodies in sera of patients with a colorectal cancer
and their association to p53 protein concentration and p53
immunohistochemistry in tumor tissue. Int J Colorectal Dis.
16:22–27. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hammel P, Boissier B, Chaumette MT,
Piedbois P, Rotman N, Kouyoumdjian JC, Lubin R, Delchier JC and
Soussi T: Detection and monitoring of serum p53 antibodies in
patients with colorectal cancer. Gut. 40:356–361. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu J, Qiu T, Pan P, Yu D, Ju Z, Qu X, Gao
X, Mao C and Wang L: Detection of serum anti-P53 antibodies from
patients with colorectal cancer in China using a combination of
P53-and phage-ELISA: Correlation to clinical parameters. Asian Pac
J Cancer Prev. 12:2921–2924. 2011.PubMed/NCBI
|
|
32
|
Tang R, Ko MC, Wang JY, Chen HH, Chen JS,
Hsu KC, Chiang JM and Hsieh LL: Humoral response to p53 in human
colorectal tumors: A prospective study of 1,209 patients. Int J
Cancer. 94:859–863. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
International Agency for Research on
Cancer, . World Health Organisation: IARC TP53 Database. Version
R18. IARC; Lyon: 2016, http://p53.iarc.fr/April. 2016
|
|
34
|
Petitjean A, Mathe E, Kato S, Ishioka C,
Tavtigian SV, Hainaut P and Olivier M: Impact of mutant p53
functional properties on TP53 mutation patterns and tumor
phenotype: Lessons from recent developments in the IARC TP53
database. Hum Mutat. 28:622–629. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Suppiah A and Greenman J: Clinical utility
of anti-p53 auto-antibody: Systematic review and focus on
colorectal cancer. World J Gastroenterol. 19:4651–4670. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Soussi T, Dehouche K and Béroud C: p53
website and analysis of p53 gene mutations in human cancer: Forging
a link between epidemiology and carcinogenesis. Hum Mutat.
15:105–113. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Levine AJ: The common mechanisms of
transformation by the small DNA tumor viruses: The inactivation of
tumor suppressor gene products: p53. Virology. 384:285–293. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Staples OD, Steele RJ and Lain S: p53 as a
therapeutic target. Surgeon. 6:240–243. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Maehara Y, Kakeji Y, Watanabe A, Baba H,
Kusumoto H, Kohnoe S and Sugimachi K: Clinical implications of
serum anti-p53 antibodies for patients with gastric carcinoma.
Cancer. 85:302–308. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ralhan R, Arora S, Chattopadhyay TK,
Shukla NK and Mathur M: Circulating p53 antibodies, p53 gene
mutational profile and product accumulation in esophageal
squamous-cell carcinoma in India. Int J Cancer. 85:791–795. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Angelopoulou K, Rosen B, Stratis M, Yu H,
Solomou M and Diamandis EP: Circulating antibodies against p53
protein in patients with ovarian carcinoma. Correlation with
clinicopathologic features and survival. Cancer. 78:2146–2152.
1996. View Article : Google Scholar : PubMed/NCBI
|
